Annexin II Proteins: An Evaluation for Type 1 Diabetes Mellitus

Annexin II (AnxII) has diverse functions including anti-coagulant activity. The studies have suggested that antibodies against annexin II (aAnxIIs) might induce thrombosis by inhibiting plasmin generation in the course of autoimmune diseases. Type 1 diabetes mellitus (DM) is also an autoimmune condition that related with thrombotic complications, but there is no study regarding aAnxII/AnxII in this disease setting. The aim of this study was to evaluate the status of AnxII and aAnxII in patients with type 1 diabetes mellitus. One hundred twenty-five patients with type 1 DM and 92 healthy controls were enrolled to the study. Serum AnxII and aAnxIIs levels were quantified by enzyme-linked immunosorbent assays. The AnxII gene expression analysis was performed by Real Time PCR. As compared to controls, patients with type 1 DM had significantly higher serum AnxII levels. There were no significant differences in terms of aAnxII levels and AnxII gene expression between patients with type 1 DM and healthy controls. The present study shows that AnxII levels are increased in patients with type 1 DM. Further studies are required to determine the clinical importance of AnxII protein in type 1 diabetes.